Literature DB >> 33246090

Worldwide prevalence of emerging parasite Blastocystis in immunocompromised patients: A systematic review and meta-analysis.

Zohreh Khorshidvand1, Salman Khazaei2, MohamadReza Amiri3, Heshmatollah Taherkhani1, Asad Mirzaei4.   

Abstract

BACKGROUND: Blastocystis is one of the most common pathogens of the human intestine, caused by an emerging parasite, which can lead to severe symptoms and even death in immunocompromised patients. We aimed to determine the global prevalence of Blastocystosis infection in people with immunodeficiency. A systematic literature search was conducted on Web of Science, Scopus, Google scholar, Science Direct and MEDLINE databases to select all observational studies reporting the prevalence of Blastocystosis infection in Worldwide, based on different diagnostic methods in immunocompromised patients of any age and published from inception to February 2019. Pooled estimates and 95% confidence intervals (95% CIs) were calculated using random effects models and in addition, the I2 statistic was calculated. The geographic distribution of studies was evaluated and the diagnosis of Blastocystis was compared by various techniques. Electronic databases were reviewed for Blastocystosis infection in HIV/AIDS, cancer and other immunocompromised patients, and meta-analyses were conducted to calculate the overall estimated prevalence. Total68 eligible studies were included. The estimated pooled prevalence rate of Blastocystosis infection in immunocompromised patients was overall 10% (95% CI, 7-13%; I2 96.04%) (P < 0.001), of whom 21% [18-25] were in Australia, 12% [4-24] in America, 11% [6-17] in Europe and 10% [5-15], 7% [3-13] in Asia and Africa, respectively. It was calculated that the estimated pooled prevalence rate of Blastocystosis infection in immunocompromised patients was overall 10% and the prevalence estimates ranged from 0.44 to 72.39. Also, overall the prevalence of parasites co-infection in immunocompromised patients was detected as 0.024%. Our finding showed that immunocompromised people show a high prevalence of Blastocystosis infection compared to the control population. Adequate information on the prevalence rate is still missing from many countries. However, current information underscore that Blastocystis should not be neglected.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blastocystis; Blastocystosis infection; Cancer patients; HIV/AIDS patients; Immunocompromised patients; Prevalence

Mesh:

Year:  2020        PMID: 33246090     DOI: 10.1016/j.micpath.2020.104615

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  4 in total

1.  Molecular identification and subtype analysis of Blastocystis in captive Asiatic black bears (Ursus thibetanus) in China's Heilongjiang and Fujian provinces.

Authors:  Yuting-Li Zhou; Nairui Zhao; Yilei Yang; Yueqi Li; Xinyu Zhang; Jiani Chen; Xiang Peng; Wei Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-08-29       Impact factor: 6.073

2.  Prevalence and Associated Factors of Blastocystis sp. Infection in Patients with Gastrointestinal Symptoms in Spain: A Case-Control Study.

Authors:  Cristina Matovelle; María Teresa Tejedor; Luis Vicente Monteagudo; Antonio Beltrán; Joaquín Quílez
Journal:  Trop Med Infect Dis       Date:  2022-09-03

3.  Blastocystis species and Gastrointestinal Symptoms in Peruvian Adults Attended in a Public Hospital.

Authors:  Mayra Ximena Robles-Cabrera; Jorge L Maguiña; Luis Gonzales-Huerta; Vicky Panduro-Correa; Bernardo Dámaso-Mata; Samuel Pecho-Silva; Ana Claudia Navarro-Solsol; Ali A Rabaan; Alfonso J Rodríguez-Morales; Kovy Arteaga-Livias
Journal:  Infect Chemother       Date:  2021-06

4.  Global epidemiology of Giardia duodenalis infection in cancer patients: a systematic review and meta-analysis.

Authors:  Farzad Mahdavi; Alireza Sadrebazzaz; Amir Modarresi Chahardehi; Roya Badali; Mostafa Omidian; Soheil Hassanipour; Ali Asghari
Journal:  Int Health       Date:  2022-01-19       Impact factor: 2.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.